Skip to main content
Premium Trial:

Request an Annual Quote

Iris Completes Purchase of AlliedPath for Up to $6M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Iris International said today it has completed its acquisition of AlliedPath for up to $6 million.

The deal was originally announced last week and includes $4.7 million in cash to AlliedPath and up to $1.3 million in an earn-out, subject to certain sales and earnings targets being met over the next three years.

AlliedPath is based in San Diego and was founded in 2008. It specializes in oncology and molecular diagnostics and received its CLIA license in 2009. Its laboratory is 10,000 square feet.

In a statement, Cesar Garcia, chairman and CEO of Iris, said that the purchase is a "significant step forward" for Iris and provides it with a CLIA-certified molecular pathology lab "offering differentiated high-value molecular diagnostic services in the rapidly growing field of personalized medicine."

The deal also offers a direct commercial channel for acceleration of Iris' NADiA nucleic acid detection immunoassay platform, Garcia added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.